Brianna Phillips’ Post

Can I introduce you to Biodesix's IQLung™ testing, your treatment guidance partner in the fight against non-small cell lung cancer (NSCLC)? This suite of tests, including the GeneStrat® targeted test, the GeneStrat NG® genomic test, and the VeriStrat® proteomic test, provides a comprehensive overview of each patient's disease state, all from a simple blood draw. With a turnaround time of just 3 business days, IQLung can expedite personalized treatment decisions. Optimize lung cancer treatment strategies with IQLung. Learn more about how to integrate IQLung into your workflow today. #PrecisionOncology #NSCLC #LungCancerTreatment

At OncoHost, we’re transforming the fight against non–small cell lung cancer with our innovative PROphetNSCLC test. This #precisiononcology tool leverages advanced #proteomics and #AI to predict clinical benefit from #immunotherapy, helping physicians make more informed, personalized treatment decisions. ✅ Why it matters: By analyzing over 7,000 proteins in a simple blood test, PROphetNSCLC provides critical insights into how a patient’s immune system is responding to treatment, allowing for better outcome prediction and improved care management. Join us in bringing the future of oncology into today’s practice. Learn more: https://bit.ly/47uMwnh #CancerResearch #LCSM

New research identified that HRD-positive ovarian cancer patients had significantly better outcomes when treated with Olaparib and uncovered ICOSLGhigh and ICOSLGhigh & DLX2high as emerging biomarkers for predicting relapse and survival leveraging the powerful AmoyDx Master Panel – the most comprehensive genomic profiling assay. These findings pave the way for more personalized and effective treatment strategies in ovarian cancer care! Dive into the study here: https://lnkd.in/g65ewH8n #OvarianCancer #PrecisionOncology #CancerResearch #Olaparib #ESMO24

Colorectal cancer (CRC) is the second-deadliest cancer in the United States. It is also highly preventable if caught early through regular screenings. #BioChain encourages you to stay informed and take action to protect your health. creening for genes using FFPE (Formalin-Fixed Paraffin-Embedded) colon cancer tissues can be a valuable approach in understanding the genetic landscape of colon cancer and identifying potential biomarkers or therapeutic targets. Collaboration with BioChain can enhance your success and impact your research. Explore our inventory: https://bit.ly/3uLvxhG #cancerawareness #cancerprevention #march

PCR stands to change the future landscape of cancer diagnostics and monitoring. Next-gen sequencing can be used for the same outcomes in cancer therapy, but it can be cost-prohibitive and difficult to justify. That said, droplet digital PCR (ddPCR) offers many of the same benefits, but with better affordability and accessibility, especially for smaller research institutions. “As more and more studies continue to demonstrate the effectiveness of ddPCR technology in ctDNA and MRD monitoring, it is likely that its use will become increasingly widespread in clinical research. Ultimately, this could lead to more personalized and effective treatments for cancer patients and improved outcomes for those living with this devastating disease.” #pcr #pcrtesting #pcrindustrynews #cancerresearch #ddPCR #PrecisionMedicine News Source: Association for Diagnostics & Laboratory Medicine - https://hubs.li/Q02Np3g-0

🚀 Exciting News for Prostate Cancer Treatment! 🚀 The FDA has approved the FoundationOne Liquid CDx as a companion diagnostic for Akeega (niraparib) and abiraterone acetate. FoundationOne Liquid is a new test used to check if people with a specific kind of prostate cancer have certain genetic changes, called BRCA mutations. Here’s how it works: Instead of taking a tissue sample from a biopsy, this test only needs a blood sample. That makes it less invasive and easier for patients. The results help doctors decide if treatments like AKEEGA or other drugs will be effective for the patient. What does this mean? More precise and personalized treatment options, leading to better outcomes and new hope for patients. It's a significant step forward in harnessing advanced diagnostics to target therapies more effectively. Kudos to the teams advancing these innovations and transforming cancer care! 🌟 #ClinicalTrial #PrecisionMedicine #PharmaInnovation

#ProstateCancer remains one of the most prevalent cancers among men globally, with roughly 1 in 44 men losing their lives to this disease. In recognition of National #ProstateCancerAwarenessMonth, ARTBIO is bringing attention to the importance of regular screenings and the urgent need for innovative therapies. Hundreds of thousands of new cases arise each year, and for those diagnosed with prostate cancer, there's a significant need for therapies that not only target tumors with greater precision and efficacy but also prioritize patient safety and comfort. At ARTBIO, we're redefining cancer care with our innovative #alpha #radioligand #therapies. Through our lead program, AB001, we aim to address the unmet need for more effective and safer therapeutic options for prostate cancer, bringing us closer to realizing the full potential of #radioligandtherapy. Learn more about our mission at www.artbio.com #ART #nuclearmedicine #biotech #RLT #radiopharmaceuticals

Let's break the chains of late-stage cancer with the revolutionary Pantum Test! This innovative test analyzes a small blood sample for specific biomarkers that are associated with various types of cancer. By identifying these biomarkers, the PanTum Test can provide early detection, allowing for timely intervention and potentially saving lives. Say goodbye to the days of uncertainty and mental anguish for families. This detects the earliest whispers of cancer cell development, empowering patients to embark on successful treatment journeys before it's too late. Join us in the fight against cancer and embrace a future where early detection saves lives.  #CancerAwareness #EarlyDetection #MedicalInnovation

Ending Day 2 of #ASCO24 with a great metastatic breast cancer oral abstract session and a recap by Dr. O’Regan on balancing the efficacy and quality of life from treatments in metastatic HR+ breast cancer. 🔐 This further highlights that patient selection is key — biomarker testing and risk stratification is crucial to determine who is going to benefit the most from a selected therapy. #biomarkertesting #genomics #precisionmedicine

🎉 Exciting milestone - we've reached over 30,000 followers! Did you know? In oncology and bioscience, the number 30,000 is packed with fascinating insights! 📊 Cancer Data: Utilizing cancer data effectively can accelerate diagnoses, potentially contributing to saving the lives of 30,000 cancer patients a year in the UK. Each data point becomes a critical piece in the puzzle of understanding and treating this complex disease.¹ 🧬Proteins: Protein folding is the process of how a long chain of amino acids forms a unique and functional shape. There are approximately 30,000 proteins that constitute the human proteome, as currently listed on Human Proteome Map (HPM) portal.² 🔬 CAR-T Cell Therapy: More than 30,000 patients with blood cancers in the United States—many of whom had few, if any, remaining treatment options available—have been treated with CAR T cell therapy since the first such therapy was approved in 2017.³ 🙌 Thank you to each and every one of you for being part of our journey. Together, we're not just celebrating a number; we're celebrating the infinite power of partnership to drive scientific discovery. #Bioscience #Oncology #ImmunoOncology #Research 1 - https://bit.ly/3JlauWY 2 -https://bit.ly/3TSoEne 3 - https://bit.ly/3TSoCM8